Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
18/08/2026 06:13
BRIEF-Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe Aug 18 (Reuters) - Ryvu Therapeutics SA RVU.WA:
LAUNCHES EARLY CLINICAL DEVELOPMENT SERVICES BUSINESS FOR BIOTECH AND PHARMA IN EUROPE
TO PROVIDE SERVICES UNDER 'KEELIRA' BRAND FOCUSING ON ONCOLOGY AND RARE INDICATIONS
Source text: ID:nEM23vfwwa
Further company coverage: RVU.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; 48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys